Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
527
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Allergic Reactions02:06

Allergic Reactions

31.9K
Overview
31.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.

Frontiers in immunology·2026
Same author

Neuronal responses to cytokines limit intestinal hypermotility and systemic effects of colonic inflammation.

iScience·2026
Same author

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same author

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

Dermatology and therapy·2026
Same author

Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.

The Journal of dermatological treatment·2026
Same author

Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies.

Dermatology and therapy·2026
Same journal

Impact of cognitive impairment and depression on asthma in older patients.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Refractory Atopic Dermatitis Unmasking Mycosis Fungoides During Targeted Therapy.

The journal of allergy and clinical immunology. In practice·2026
Same journal

ASTHMA CONTROL BEFORE AND AFTER CHANGING GAS STOVES TO ELECTRIC STOVES.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Multiplex Cytokine LTT Reveals Strong T Cell Responses to Multiple Drugs in NIDHR-Associated Multiple Drug Hypersensitivity.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Allergic Fungal Rhinosinusitis: Distinct Clinical Features, Diagnostic Challenges, and Evolving Therapeutic Strategies.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Effectiveness of treatment with tezepelumab in patients with severe asthma, smoking asthmatics and patients with severe Asthma and COPD: A real-world cohort study.

The journal of allergy and clinical immunology. In practice·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Updates on Kinase Inhibitors in Allergy.

Melanie C Dispenza1, Brian S Kim2

  • 1Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

The Journal of Allergy and Clinical Immunology. in Practice
|November 24, 2025
PubMed
Summary
This summary is machine-generated.

Kinase inhibitors like Bruton

Keywords:
AnaphylaxisAtopic dermatitisBruton’s tyrosine kinaseChronic urticariaFood allergyJanus kinaseKITKinase

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

Area of Science:

  • Immunology and Pharmacology
  • Drug Discovery and Development

Background:

  • Kinase inhibitors are revolutionizing allergy treatment, moving beyond cancer therapy.
  • Advances in selective inhibitor design enhance safety and efficacy for immune-mediated disorders.

Purpose of the Study:

  • To review recent advancements in kinase inhibitor development for allergic diseases.
  • To summarize mechanistic rationale, clinical trial findings, and safety profiles of key inhibitors.

Main Methods:

  • Review of current literature on Bruton's tyrosine kinase (BTK), Janus kinase (JAK), and KIT inhibitors.
  • Analysis of clinical trial data and safety profiles for approved and emerging therapies.
  • Discussion of practical considerations for integrating these inhibitors into clinical practice.

Main Results:

  • BTK inhibitors provide rapid control of IgE-mediated reactivity, approved for chronic urticaria.
  • JAK inhibitors show significant anti-inflammatory and anti-pruritic effects in atopic dermatitis.
  • KIT inhibitors offer new treatment avenues for mastocytosis and chronic urticaria via mast cell suppression.

Conclusions:

  • Kinase inhibitors represent a significant therapeutic advancement in managing allergic and immune-mediated diseases.
  • Targeted inhibition of BTK, JAK, and KIT pathways offers effective treatment options with manageable safety profiles.